{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}],"title":"On Treatment (days 1 to 5 of SBRT delivery)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"6 weeks"}],"denoms":[{"counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"15"}],"units":"Participants"}],"description":"Evaluation of delivering SBRT to the prostate using non-uniform dosing. The investigators will evaluate the potential for added grade 3 rectal toxicity with the use of a simultaneous integrated boost (SIB - Arm A). Acute toxicities were defined as occurring on-treatment or within 6 weeks.","groups":[{"description":"Incidence of moderate GU toxicities on-treatment or within 6 weeks.","id":"OG000","title":"Grade 2 Toxicities: Arm A"},{"description":"Incidence of moderate GU toxicities on-treatment or within 6 weeks.","id":"OG001","title":"Grade 2 Toxicities: Arm B"},{"description":"Incidence of severe GU toxicities on-treatment or within 6 weeks.","id":"OG002","title":"Grade 3 Toxicities: Arm A"},{"description":"Incidence of severe GU toxicities on-treatment or within 6 weeks.","id":"OG003","title":"Grade 3 Toxicities: Arm B"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"during treatment (days 1 to 5), 6 week follow up","title":"Number of Participants Experiencing Genitourinary (GU) Acute Toxicity","type":"PRIMARY","unitOfMeasure":"Participants"}